Latest Publications

Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, phase I clinical trial.

https://pubmed.ncbi.nlm.nih.gov/33098996/ Authors: Hiltbrunner S, Bristchgi C, Schuberth P, Bankel L, Nguyen-Kim TDL, Gulati P et al. Ann Oncol 2021;32(1):120-121

Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation.

https://pubmed.ncbi.nlm.nih.gov/32897885/ Authors: Shah GL, DeWolf S, Lee YJ, Tamari R, Dahi PB, Lavery JA et al. J Clin Invest 2020;130(12):6656-6667.

Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia.

https://pubmed.ncbi.nlm.nih.gov/33230103/ Authors: An F, Wang H, Liu Z, Wu F, Zhang J, Tao Q et al. Nat Commun 2020;11(1):5928

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.

https://pubmed.ncbi.nlm.nih.gov/32888407/ Authors: Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J et al. Lancet 2020;396(10254):839-852.

Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.

https://pubmed.ncbi.nlm.nih.gov/33091355/ Authors: Anagnostou T, Riaz IB, Hashmi SK, Murad MH, Kenderian SS. Lancet Haematol 2020;7(11):e816-e826.

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.

https://pubmed.ncbi.nlm.nih.gov/33020647/ Authors: Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA et al. Nat Med 2020;26(10):1569-1575.

Commercial anti-CD19 CAR T cell therapy fo patients with relapsed/refractory aggressive B cell lymphoma in a European center.

https://pubmed.ncbi.nlm.nih.gov/32744738/ Authors: Sesques P, Ferrant E, Safar V, Wallet F, Tordo J, Dhomps A et al. Am J Hematol 2020;95(11):1324-1333.

Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma.

https://pubmed.ncbi.nlm.nih.gov/32448949/ Authors: Goto H, Makita S, Kato K, Tokushige K, Fujita T, Akashi K et al. Int J Clin Oncol 2020;25(9):1736-1743.